GC Medical Science녹십자엠에스
142280 · KOSDAQ · ₩142280 · 녹십자엠에스
₩3,395▲ ₩115 (3.51%)End-of-day · Oct 28, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | ₩108B | ₩104B | ₩94B | ₩113B | ₩102B |
| Cost of sales | ₩93B | ₩89B | ₩80B | ₩100B | ₩100B |
| Gross profit | ₩15B | ₩15B | ₩14B | ₩13B | ₩1.7B |
| Operating income | ₩2.9B | ₩2.3B | ₩1.8B | −₩1.3B | −₩20B |
| Net income | ₩3.5B | ₩3.4B | ₩1.9B | −₩3.1B | −₩21B |
| Net income to shareholders | ₩3.7B | ₩3.6B | ₩1.8B | −₩3.6B | −₩21B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Total assets | ₩91B | ₩88B | ₩91B | ₩96B | ₩96B |
| Current assets | ₩41B | ₩39B | ₩43B | ₩50B | ₩52B |
| Cash and equivalents | ₩373M | ₩678M | ₩5.7B | ₩8.8B | ₩1.8B |
| Total liabilities | ₩44B | ₩45B | ₩54B | ₩61B | ₩58B |
| Current liabilities | ₩35B | ₩37B | ₩47B | ₩39B | ₩49B |
| Borrowings | ₩11B | ₩0 | ₩0 | ₩15B | ₩30B |
| Total equity | ₩46B | ₩43B | ₩37B | ₩36B | ₩38B |
| Shareholders' equity | ₩44B | ₩41B | ₩34B | ₩33B | ₩36B |
Cash flow
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | ₩7.2B | ₩3.7B | ₩4.2B | ₩11B | −₩18B |
| Capital spending | ₩4.7B | ₩3.2B | ₩5.6B | ₩3.4B | ₩3.6B |
| Free cash flow | ₩2.5B | ₩445M | −₩1.4B | ₩7.5B | −₩22B |
Consolidated where available. Amounts in won.
Also known as: GC Medical Science / 녹십자엠에스 / 142280 / KRX:142280
Source: KRX statistical information